Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and tissues derived from a patient's own (autologous) cells. The Company's lead product candidate, the Tengion Neo-Bladder™, is currently in Phase II clinical trials in the United States in pediatric patients with spina bifida, adult patients with spinal cord injury and adult patients with urge incontinence. A successful academic human clinical experience with a urinary Neo-Bladder was reported in The Lancet in April 2006 by investigators from the Children's Hospital Boston.